Caffeine / BDNF Cancer Research Results

Caff, Caffeine: Click to Expand ⟱
Features:
Caffeine is a natural chemical with stimulant effects. It is found in coffee, tea, cola, cocoa, guarana, yerba mate, and over 60 other products.

Caffeine (CAF; 1,3,7-trimethylxanthine) — dietary methylxanthine (natural product / drug) found in coffee/tea/cacao and used in OTC stimulants and some analgesic combinations. Sources: coffee/tea, supplements, OTC meds.

Primary mechanisms (conceptual rank):
1) Adenosine receptor antagonism (A1/A2A) → wakefulness, neuromodulation
2) ↑ Catecholamines / CNS arousal → performance + mood effects
3) PDE inhibition (cAMP/cGMP ↑) (high concentration only)
4) Cell-cycle checkpoint interference (ATM/ATR-related) (high concentration only)

Bioavailability / PK relevance: Rapid oral absorption; widely distributed (including CNS); hepatic metabolism (CYP1A2) with large inter-individual variability; tolerance develops with habitual use.

In-vitro vs oral exposure: Many “anti-cancer” mechanisms rely on supra-physiologic concentrations (PDE inhibition, checkpoint override) vs typical dietary plasma levels; clinically relevant mechanism is adenosine antagonism. This is a major translation constraint. Physiologic human exposures after ordinary intake are in the low micromolar range relevant to adenosine receptor occupancy, whereas many anticancer in-vitro effects commonly attributed to caffeine, especially PDE inhibition, Ca²⁺ release, and checkpoint override, usually require far higher concentrations, often approaching high-micromolar to millimolar ranges.

Clinical evidence status: Extensive human data for alertness/performance; oncology evidence is mainly epidemiologic + preclinical (no anticancer indication).

Natural stimulant

-Caffeine appears to interact with several pathways relevant to cancer biology—including adenosine receptor signaling, DNA damage response, cell cycle regulation, apoptosis, PI3K/Akt/mTOR, and NF-κB
—Its overall impact likely depends on the cancer type, stage, microenvironment, and the dosage administered

Caffeine — Cancer vs Normal Cell Pathway Map

RankPathway / AxisCancer CellsNormal CellsTSFPrimary EffectNotes / Interpretation
1Adenosine signaling (A1/A2A antagonism) ↓ adenosine-mediated suppression (context-dependent)↑ arousal/neuromodulationP/R Immune + signaling tone shift A2A antagonism can be immunostimulatory in tumor-microenvironment contexts; not a tumor-directed cytotoxin and highly context-dependent.
2cAMP signaling / catecholamine tone ↔ (context-dependent)↑ (acute stimulation)P/R Systemic stimulation Stress-hormone effects can be bidirectional for cancer biology depending on context; not a central anticancer mechanism.
3DNA damage response checkpoints (ATM/ATR) ↓ checkpoints (high concentration only)↓ checkpoints (high concentration only)P/R S/G2 checkpoint override Classic in vitro effect used to radiosensitize/chemosensitize; translation limited by concentration requirements.
4Cell cycle / proliferation ↓ or ↔ (model-dependent; high concentration only)↔R/G Cytostatic effects (experimental) Observed in vitro; not consistent at dietary exposures.
5Apoptosis ↑ (high concentration only)↔R/G Experimental cytotoxicity Typically downstream of checkpoint disruption/ROS stress in vitro.
6PDE inhibition ↑ cAMP/cGMP (high concentration only)↑ cAMP/cGMP (high concentration only)P/R Second-messenger amplification PDE inhibition is not dominant at typical intake; becomes relevant only at higher exposures.
7ROS ↔ / ↑ (high concentration only)↔P/R Not a primary redox drug Some models show oxidative stress at high dose; not canonical at physiologic exposure.
8NRF2 ↔↔R/G No primary modulation Not a canonical caffeine-first axis.
9HIF-1α ↔ (limited; model-dependent)↔G Not primary Any hypoxia-pathway effects are indirect and not robustly classed as core.
10Ferroptosis ↔ (not established)↔R/G Not canonical No consistent ferroptosis program attributed to caffeine.
11Ca²⁺ signaling ↔↔P/R No primary role Not a dominant mechanistic axis at typical intake.
12Clinical Translation Constraint ↓ (constraint)↓ (constraint)— Exposure + tolerance + sleep effects Most tumor-directed mechanisms require high concentrations; chronic use limited by sleep disruption/anxiety in susceptible individuals and tolerance to stimulant effects.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Caffeine — AD relevance: Strong mechanistic fit via adenosine A2A antagonism (synaptic plasticity + neuroinflammation modulation). Human data support acute attention benefits; dementia/AD risk signals are largely observational (not disease-modifying approval).

Primary mechanisms (conceptual rank):
1) A2A antagonism → ↑ synaptic efficiency / plasticity
2) ↓ Neuroinflammation (microglial tone; cytokine signaling) (context-dependent)
3) ↓ Aβ/tau-associated toxicity pathways (preclinical; model-dependent)
4) Cerebrovascular / glymphatic-sleep tradeoffs (alertness vs sleep architecture effects)

Bioavailability / PK relevance: Rapid CNS penetration; effects are acute (minutes–hours) but chronic patterns depend on tolerance and sleep timing.

Clinical evidence status: Supportive (symptom/attention); AD disease-modifying efficacy not established.

Caffeine — AD / Neurodegeneration Pathway Map

RankPathway / AxisCellsTSFPrimary EffectNotes / Interpretation
1Adenosine A2A antagonism (synaptic plasticity) ↑P/R Improved signaling efficiency Core neuro mechanism; overlaps with the rationale for A2A antagonists in neurodegeneration frameworks.
2Neuroinflammation (microglial activation; cytokines) ↓ (context-dependent)R/G Lower inflammatory stress Often attributed to adenosine-pathway modulation; magnitude is model- and state-dependent.
3ROS / mitochondrial stress ↔ / ↓ (supportive)P/R Resilience support (secondary) Not a primary antioxidant; changes are typically indirect via signaling state and inflammation.
4Aβ / tau-associated pathology ↔ / ↓ (preclinical; model-dependent)G Reduced proteotoxic stress (hypothesis) Evidence is stronger in models than in biomarker-confirmed human AD studies.
5Ca²⁺ excitotoxicity interplay ↔ (indirect)P/R Not primary Could be secondary to synaptic modulation; treat as secondary unless explicit Ca²⁺ endpoints exist.
6Sleep architecture / glymphatic coupling ↑ alertness; ↓ sleep (timing-dependent)R/G Tradeoff axis Potential benefit via daytime function but potential harm if it chronically degrades sleep quality (sleep is relevant to amyloid clearance hypotheses).
7Clinical Translation Constraint ↓ (constraint)— Timing + tolerance + heterogeneity Benefits depend strongly on dosing/timing and individual sensitivity; not disease-modifying therapy.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
BDNF, brain-derived neurotrophic factor: Click to Expand ⟱
Source:
Type:
Brain-Derived Neurotrophic Factor (BDNF) is a key neurotrophin (a type of growth factor) involved in brain health, and its role in Alzheimer’s Disease (AD) has been extensively studied.
-AD patients often have lower BDNF levels in key brain regions, such as the hippocampus and cortex.
-This reduction correlates with cognitive decline and brain atrophy.
-BDNF normally protects neurons from Aβ toxicity
-Exercise and cognitive training have been shown to boost BDNF levels and may slow cognitive decline.
- natural compounds (like curcumin or flavonoids) may also upregulate BDNF.
Scientific Papers found: Click to Expand⟱
4161- Caff,    Chronic caffeine prevents changes in inhibitory avoidance memory and hippocampal BDNF immunocontent in middle-aged rats
- in-vivo, AD, NA
*BDNF↑, *cognitive↑, *memory↑,
4267- Caff,    Caffeine‐mediated BDNF release regulates long‐term synaptic plasticity through activation of IRS2 signaling
- in-vivo, NA, NA
*cognitive↑, *memory↑, *Mood↑, *BDNF↑, *TrkB↑,
4268- Caff,    Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects
- Study, NA, NA
*BDNF↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Synaptic & Neurotransmission ⓘ

BDNF↑, 3,   TrkB↑, 1,  

Functional Outcomes ⓘ

cognitive↑, 2,   memory↑, 2,   Mood↑, 1,  
Total Targets: 5

Scientific Paper Hit Count for: BDNF, brain-derived neurotrophic factor
3 Caffeine
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:52  Target#:1356  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page